Table 2.
Hematological and biochemical measurements of the study population
| Variable | CIN | P Value | |
|---|---|---|---|
| No, n = 818 | Yes, n = 77 | ||
| Age, y | 57.4 ± 12.5 | 69.0 ± 14.0 | <0.001 |
| Female sex | 187 (22.9) | 31 (40.3) | 0.001 |
| BMI, kg/m2 | 28.0 ± 4.3 | 27.3 ± 4.5 | 0.218 |
| HTN | 297 (36.3) | 45 (58.4) | <0.001 |
| DM | 217 (26.5) | 32 (41.6) | 0.005 |
| Current smoker | 471 (57.6) | 17 (22.1) | <0.001 |
| Hypercholesterolemia | 220 (26.9) | 19 (24.7) | 0.879 |
| Prior CABG | 19 (2.3) | 4 (5.2) | 0.128 |
| SBP, mm Hg | 128 ± 24 | 126 ± 29 | 0.612 |
| DBP, mm Hg | 78 ± 14 | 77 ± 17 | 0.461 |
| Infarct location | 0.113 | ||
| Anterior | 360 (44.0) | 40 (51.9) | |
| Inferior | 394 (48.2) | 28 (36.4) | |
| Other (lateral, true posterior) | 64 (7.8) | 9 (11.7) | |
| LVEF, % | 46 ± 10 | 40 ± 11 | <0.001 |
| Killip class ≥2 on admission | 45 (5.5) | 10 (13.0) | 0.009 |
| Time from chest pain to primary PCI | 0.240 | ||
| 0–6 hours | 652 (79.7) | 57 (74.0) | |
| 6–12 hours | 166 (20.3) | 20 (26.0) | |
| WBC count, ×109/L | 11.7 ± 3.4 | 12.6 ± 3.9 | 0.034 |
| Platelet count, ×109/L | 246 ± 67 | 250 ± 90 | 0.653 |
| Hgb, g/dL | 14.4 ± 1.7 | 12.6 ± 3.9 | <0.001 |
| Glucose, mg/dL | 153 ± 78 | 174 ± 90 | 0.030 |
| Cr, mg/dL | 1.06 ± 0.24 | 1.29 ± 0.40 | <0.001 |
| GFR, mL/min/1.73 m2 | 75.9 ± 18.8 | 55.1 ± 21.1 | <0.001 |
| Peak TnT, ng/mL | 2758 (843–7824) | 5967 (1596–10 000) | 0.008 |
| Postprocedural no‐reflow phenomenon | 132 (16.1) | 27 (35.1) | <0.001 |
| Multivessel CAD | 418 (51.1) | 50 (64.9) | 0.020 |
| Total procedure time, min | 36.7 ± 16.4 | 38.9 ± 17.9 | 0.406 |
| Total amount of contrast, mL | 170 ± 73 | 168 ± 75 | 0.862 |
| SYNTAX score | 16.4 ± 8.5 | 20.8 ± 9.6 | <0.001 |
| Stent diameter, mm | 3.19 ± 0.44 | 3.12 ± 0.39 | 0.177 |
| Total stent length, mm | 25.8 ± 12.4 | 28.9 ± 13.3 | 0.038 |
| ST‐segment resolution in ECG | 573 (70.1) | 32 (42.5) | <0.001 |
| Presence of fQRS | 213 (26.0) | 63 (81.8) | <0.001 |
| In‐hospital mortality | 8 (1.0) | 15 (19.5) | <0.001 |
| hs‐CRP, mg/L | 7.36 (2.81–10.60) | 10.6 (5.08–14.92) | 0.005 |
| Prior medications | |||
| ASA | 81 (10.0) | 10 (13.3) | 0.557 |
| β‐Blocker | 157 (19.3) | 18 (23.3) | 0.398 |
| Angiotensin‐aldosterone system antagonist | 228 (27.9) | 28 (36.7) | 0.210 |
| Statin | 56 (6.9) | 7 (9.3) | 0.590 |
Abbreviations: ASA, acetylsalicylic acid (aspirin); BMI, body mass index; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CIN, contrast‐induced nephropathy; Cr, creatinine; DBP, diastolic blood pressure; DM, diabetes mellitus; ECG, electrocardiography; fQRS, fragmented QRS complex; GFR, glomerular filtration rate; Hgb, hemoglobin; hs‐CRP, high‐sensitivity C‐reactive protein; HTN, hypertension; IQR, interquartile range; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SD, standard deviation; TnT, troponin T; WBC, white blood cell.
Data are presented as n (%), mean ± SD, or median (IQR).